Loading stock data…
$0.72-0.03 (-3.62%)
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Filana Therapeutics, Inc. in the Healthcare sector is trading at $0.72 with a market capitalization of $46M. Wall Street consensus targets $6.50 (2 analysts), implying a +807.2% move over the next 12 months. The stock is currently near its 52-week low of $0.67, remaining 50.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.39M↑ | -$11.17M↑ | -$14.29M↓ | -$11.86M↑ | -$45.39M |
| Net Income | -$8.60M↑ | -$10.33M↑ | -$12.54M↓ | -$10.81M↑ | -$44.22M |
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's dise...